Baird Medical Advances MWA Training with Expert-Led Course at Columbia Thyroid Center

NEW YORK, Feb. 10, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a leader in microwave ablation (MWA) technology, remains committed to advancing physician education and recently supported Dr. Hosai Todd-Hesham's participation in a specialized MWA training program at the Columbia Thyroid Center in New York City.

Led by Dr. Jennifer Kuo, Director of the Interventional Endocrinology Program and Program Director of the Endocrine Surgery Fellowship at Columbia University's Department of Surgery, the two-day course provided in-depth instruction on MWA techniques, procedural safety, and clinical applications. The program attracted physicians from the United States and Mexico, including Dr. Hosai Todd-Hesham, an Otolaryngology specialist from Maryland ENT Associates, and Dr. Camilo González Velázquez, Associate Professor and Endocrinologist at Hospital Universitario Dr. José E. González.

During the hands-on training session, Dr. Hesham, under the expert guidance of Dr. Kuo, performed simulated procedures using a thyroid model. She focused on mastering device operation, enhancing ablation precision, and making real-time procedural adjustments. This structured training allowed her to systematically refine her expertise in thyroid MWA, further strengthening her skills in minimally invasive techniques.

The live case observation session proved highly beneficial for the participating physicians. Through three procedures, they gained deeper insights into MWA's preoperative planning, intraoperative techniques, and postoperative patient management. The practical nature of the training received high praise from attendees. Dr. Hesham described the experience as a solid foundation that enhanced her confidence and interest in microwave ablation technology. Dr. Velázquez emphasized the irreplaceable value of hands-on clinical experience, noting that many procedural nuances extend beyond textbook knowledge. One notable case involved the ablation of a 5cm thyroid nodule, where the patient experienced significant symptom relief and a smooth recovery, further demonstrating MWA's precision and minimally invasive advantages in treating larger nodules.

As a pioneer in microwave ablation, Baird Medical is dedicated to accelerating the adoption of innovative, minimally invasive treatments through specialized training and collaboration. By expanding its global MWA education network, the Company aims to provide physicians with standardized and comprehensive training to enhance procedural expertise. Through these efforts, Baird Medical empowers more doctors to deliver safer, more effective treatments, improving outcomes and quality of life for patients worldwide.

About Baird Medical
Baird Medical is a leading provider of minimally invasive microwave ablation (MWA) technology, offering advanced treatment solutions for conditions such as thyroid nodules, breast disease, uterine fibroids, and liver cancer. A publicly traded company on NASDAQ, Baird Medical is dedicated to enhancing patient care through precision, efficiency, and safety in its innovative medical devices. For more information, please visit https://bairdmed.com/

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts and generally relate to future events or Baird Medical's future financial or operational performance. In some cases, you can identify forward-looking statements by terminology such as "may," "might," "will," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue," or the negative of these terms or other similar expressions.

These forward-looking statements are subject to risks, uncertainties, and assumptions that could cause actual results or outcomes to differ materially from those expressed or implied. These statements are based on estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. Risks and uncertainties may emerge over time, and it is not possible to anticipate all potential factors that could affect Baird Medical's business and financial performance.

Factors that could cause actual results to differ materially include, but are not limited to: (1) the risk that Baird Medical may not achieve its expansion goals in the United States, China, or other markets; (2) changes in economic, regulatory, or market conditions that impact Baird Medical's operations; (3) the ability to realize anticipated benefits from ongoing business initiatives or strategic transactions; (4) regulatory developments and compliance with applicable laws; (5) risks related to the development, commercialization, and market acceptance of Baird Medical's products; and (6) other risks and uncertainties detailed in Baird Medical's filings with the SEC.

Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Baird Medical undertakes no obligation to update or revise forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. All forward-looking statements in this press release are qualified in their entirety by this cautionary statement.

Contact:
Eric Huang, PR Liaison
Baird Medical Investment Holdings Ltd.
Phone: +1 (888) 508-6228
Email: ir@bairdmed.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-medical-advances-mwa-training-with-expert-led-course-at-columbia-thyroid-center-302371852.html

SOURCE BDMD